Edesa Biotech Inc. (NASDAQ:EDSA) went up by 7.91% from its latest closing price compared to the recent 1-year high of $19.10. The company’s stock price has collected 4.45% of gains in the last five trading sessions. Press Release reported on 04/22/21 that Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome
Is It Worth Investing in Edesa Biotech Inc. (NASDAQ :EDSA) Right Now?
Plus, the 36-month beta value for EDSA is at 0.65. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Edesa Biotech Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $18.00. EDSA currently public float of 6.46M and currently shorts hold a 1.21% ratio of that float. Today, the average trading volume of EDSA was 284.32K shares.
EDSA’s Market Performance
EDSA stocks went up by 4.45% for the week, with a monthly jump of 16.55% and a quarterly performance of 9.17%, while its annual performance rate touched 178.72%. The volatility ratio for the week stands at 13.37% while the volatility levels for the past 30 days are set at 7.75% for Edesa Biotech Inc.. The simple moving average for the period of the last 20 days is 17.53% for EDSA stocks with a simple moving average of 6.64% for the last 200 days.
EDSA Trading at 17.73% from the 50-Day Moving Average
After a stumble in the market that brought EDSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.71% of loss for the given period.
Volatility was left at 7.75%, however, over the last 30 days, the volatility rate increased by 13.37%, as shares surge +12.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.80% lower at present.
During the last 5 trading sessions, EDSA rose by +4.45%, which changed the moving average for the period of 200-days by +24.76% in comparison to the 20-day moving average, which settled at $5.61. In addition, Edesa Biotech Inc. saw 54.12% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at EDSA starting from Brooks Michael J, who purchase 3,500 shares at the price of $5.19 back on Mar 25. After this action, Brooks Michael J now owns 13,241 shares of Edesa Biotech Inc., valued at $18,165 using the latest closing price.
Nijhawan Pardeep, the Chief Executive Officer of Edesa Biotech Inc., purchase 3,000 shares at $5.25 during a trade that took place back on Mar 25, which means that Nijhawan Pardeep is holding 545,312 shares at $15,750 based on the most recent closing price.
Stock Fundamentals for EDSA
Current profitability levels for the company are sitting at:
- -1946.72 for the present operating margin
- +77.14 for the gross margin
The net margin for Edesa Biotech Inc. stands at -1935.59. The total capital return value is set at -88.11, while invested capital returns managed to touch -88.03. Equity return is now at value -118.10, with -84.10 for asset returns.
Based on Edesa Biotech Inc. (EDSA), the company’s capital structure generated 1.80 points at debt to equity in total, while total debt to capital is 1.77. Total debt to assets is 1.53, with long-term debt to equity ratio resting at 1.42. Finally, the long-term debt to capital ratio is 1.02.
When we switch over and look at the enterprise to sales, we see a ratio of 197.35, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 2.16 and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.30.